JAK2 and ovarian carcinoma: Notably, they discovered that ALKBH5 overexpression promoted tumor growth and chemoresistance to cisplatin in epithelial ovarian cancer by activating the JAK2/STAT3 pathway, consistent with previous studies which reported that the activation of the JAK2/STAT3 signaling pathway contributes to pro-tumor effect and chemotherapy resistance in several cancer types [77,78,79].